Ohta H
Department of Third Medicine, Asahikawa Medical College, Japan.
Hokkaido Igaku Zasshi. 1991 Jul;66(4):545-57.
beta-Glucuronidase, a lysosomal hydrolase, was purified from human liver tissue, and an enzyme-linked immunosorbent assay was developed using specific antibody against the enzyme. Using the assay procedure, the serum immunoreactive beta-glucuronidase (beta-glucuronidase) was determined in 190 patients with various liver diseases and in 53 healthy controls to examine whether or not the serum level of beta-glucuronidase would successfully reflect the degree of histological hepatic cell necrosis. beta-Glucuronidase was also determined at regular intervals in 28 patients with chronic hepatitis to investigate the clinical usefulness of serial measurement of the enzyme to predict the histological progression of hepatitis. These 28 patients could be subdivided into three groups, "continuously low type", "labile type" and "elevated type" according to the profiles of fluctuation of serum beta-glucuronidase values. Serum beta-glucuronidase was significantly increased in patients with hepatoma, liver cirrhosis and chronic active hepatitis compared with normal controls. There was significant positive correlation between the beta-glucuronidase and the degree of hepatic cell necrosis determined by histological observation, on the other hand, there was no statistical correlation between the transaminase activities and the degree of hepatic cell necrosis. It was confirmed in immunohistochemical study that the increased beta-glucuronidase in serum has been released from necrotic hepatic cells into blood stream. It was speculated that the elevation of serum transaminase activities had resulted from the alteration in the membrane permeability of hepatic cells rather than from hepatocellular necrosis. Histological progression of hepatitis was found in 8 of 10 patients (80%) of "labile" and "elevated type", while it was found only 3 of 18 patients (16.7%) of "continuously low type". These results suggested that the serial measurement of beta-glucuronidase could be used for an indicator to predict the histological progression of hepatitis.
β-葡萄糖醛酸酶是一种溶酶体水解酶,从人肝组织中纯化得到,并使用针对该酶的特异性抗体开发了酶联免疫吸附测定法。采用该测定方法,对190例各种肝病患者和53例健康对照者的血清免疫反应性β-葡萄糖醛酸酶(β-葡萄糖醛酸酶)进行了测定,以检查β-葡萄糖醛酸酶的血清水平是否能成功反映肝组织学肝细胞坏死程度。还对28例慢性肝炎患者定期测定β-葡萄糖醛酸酶,以研究该酶的系列测定对预测肝炎组织学进展的临床实用性。根据血清β-葡萄糖醛酸酶值的波动情况,这28例患者可分为三组:“持续低类型”、“不稳定类型”和“升高类型”。与正常对照相比,肝癌、肝硬化和慢性活动性肝炎患者的血清β-葡萄糖醛酸酶显著升高。另一方面,β-葡萄糖醛酸酶与组织学观察确定的肝细胞坏死程度之间存在显著正相关,而转氨酶活性与肝细胞坏死程度之间无统计学相关性。免疫组织化学研究证实,血清中升高的β-葡萄糖醛酸酶已从坏死的肝细胞释放到血流中。推测血清转氨酶活性升高是由于肝细胞的膜通透性改变而非肝细胞坏死所致。“不稳定”和“升高类型”的10例患者中有8例(80%)出现肝炎组织学进展,但“持续低类型”的18例患者中仅3例(16.7%)出现。这些结果表明,β-葡萄糖醛酸酶的系列测定可作为预测肝炎组织学进展的指标。